NeuroSense Therapeutics Ltd. (NRSN) AI Dilution Summary

The company is funding itself through its ATM program with JonesTrading Institutional Services LLC. The program is authorised to $3,789,822, and 338,141 shares were sold since the program began through 2026-07-31; sales after that date are not yet reported. Cash was $231,000 at 2026-06-30 against estimated monthly burn of $331,667, and ATM sales after that balance-sheet date raised $481,759 net through 2026-07-30.